Skip to main content Skip to main navigation menu Skip to site footer
International Journal of Nutrology
Review
DOI: 10.54448/ijn23225
Submitted: 06-18-2023
Published: 06-18-2023

Major clinical outcomes of vitamin D deficiency in inflammatory bowel diseases: a systematic and integrative review

IMEG – Institute of Medicine of Goiás. Goiânia, Goiás, Brazil
Vitamin D Hypovitaminosis D Inflammatory bowel diseases Crohn's disease Immunodeficiency

Abstract

Introduction: Clinical studies have proven the direct correlation of vitamin D deficiency in patients suffering from inflammatory bowel diseases, such as Crohn's disease, with an average age of 41 years and more frequently in women. Vitamin D seems to interact with the immune system through its action on the regulation and differentiation of cells such as lymphocytes, macrophages, and natural killer (NK) cells, in addition to interfering with the production of cytokines. Objective: It was to present, through a systematic review, the main clinical outcomes of the correlation of vitamin D deficiency and inflammatory bowel diseases, highlighting Crohn's disease. Methods: The systematic review rules of the PRISMA Platform were followed. The research was carried out from August to October 2022 in the Scopus, PubMed, Science Direct, Scielo, and Google Scholar databases. The quality of the studies was based on the GRADE instrument and the risk of bias was analyzed according to the Cochrane instrument. Results and Conclusion: A total of 207 articles were found, and 142 articles were evaluated and 117 were included in this systematic review. Considering the Cochrane tool for risk of bias, the overall assessment resulted in 20 studies with a high risk of bias and 28 studies that did not meet GRADE. Most studies showed homogeneity in their results, with R2 =95.7% >50%. It was shown that the highest prevalence of low serum levels of vitamin D is among patients suffering from Crohn's disease and other inflammatory bowel diseases when compared to a control group. However, more comprehensive studies are still needed, especially those that aim to evaluate serum vitamin D in values related to clinical treatment and also the effects of vitamin D supplementation on disease activity and mucosal healing. Thus, it will be possible to evaluate in a relevant way, the replacement of vitamin D in the remission of Crohn's disease, optimizing the treatment of patients and corroborating the improvement in quality of life.

Metrics

Metrics Loading ...

References

  1. Priscilla Clímaco Rebouças, João Gomes Netinho, Geni Satomi Cunrath, Luiz Sergio Ronchi, Marcelo Maia Caixeta de Melo, Francisco de Assis Gonçalves Filho, et al. Hypovitaminosis D in patients with Crohn’s disease. j coloproctol (rio j). 2 0 1 6;36(2):59– 63.
  2. Basson A. Vitamin D. Crohn’s disease in the adult patient: a review. J Parenter Enteral Nutr. 2014;38:438–58.
  3. Hassan V, Hassan S, Seyed-Javad P. Association between Serum 25 (OH) vitamin D concentrations and inflammatory bowel diseases (IBDs) activity. Med J Malaysia. 2013;68:34–8.
  4. Xu XR, Liu CQ, Feng BS. Dysregulation of mucosal immune response in pathogenesis of inflammatory bowel disease. World J Gastroenterol. 2014;20:3255–64.
  5. Dumitrescu G, Mihai C, Dranga M. Serum 25-hydroxyvitamin D concentrations and inflammatory bowel disease characteristics in Romania. World J Gastroenterol. 2014;20:2392–6.
  6. Tan B, Li P, Lv H. Vitamin D levels and bone metabolism in Chinese adult patients with inflammatory bowel disease. J Dig Dis. 2014;15:116–23.
  7. Veit LE, Maranda L, Fong J. The vitamin D status in inflammatory bowel disease. PLoS ONE. 2014;9(7):e101583.
  8. Raftery T, O’Morain CA, O’Sullivan M. Vitamin D: new roles and therapeutic potential in inflammatory bowel disease. Curr Drug Metab. 2012;13:1294–302.
  9. De Bruyn JR, Van Heeckeren R, Ponsioen CY. Vitamin D deficiency in Crohn’s disease and healthy controls: a prospective case–control study in the Netherlands. J Crohns Colitis. 2014;8:1267–73.
  10. Cantorna MT, Waddell A. The vitamin D receptor turns off chronically activated T cells. Ann NY Acad Sci. 2014;1317:70–5.
  11. Adorini L, Penna G. Control of autoimmune diseases by the vitamin D endocrine system. Nat Clin Pract Rheumatol. 2008;4:404–12.
  12. Cantorna MT, Zhu Y, Froicu M. Vitamin D status, 1,25-dihydroxyvitamin D3, and the immune system. Am J Clin Nutr. 2004;80:1717S–20S.
  13. Hong Q, Xu J, Xu S. Association between serum 25-hydroxyvitamin D and disease activity, inflammatory cytokines and bone loss in patients with rheumatoid arthritis. Rheumatology. 2014;53:1994–2001.
  14. Niino M, Fukazawa T, Miyazaki Y. Suppression of IL-10 production by calcitriol in patients with multiple sclerosis. J Neuroimmunol. 2014;270:86–94.
  15. Turk N, Turk Z. Prevalent hypovitaminosis D in Crohn’s disease correlates highly with mediators of osteoimmunology. Clin Invest Med. 2014;37:E154–62.
  16. Ham M, Longhi MS, Lahiff C. Vitamin D levels in adults with Crohn’s disease are responsive to disease activity and treatment. Inflamm Bowel Dis. 2014;20:856–60.
  17. Jantchou P, Clavel-Chapelon F, Racine A. High residential sun exposure is associated with a low risk of incident Crohn’s disease in the prospective E3N cohort. Inflamm Bowel Dis. 2014;20:75–81.
  18. Ananthakrishnan AN, Cagan A, Gainer VS. Normalization of plasma 25-hydroxy vitamin D is associated with reduced risk of surgery in Crohn’s disease. Inflamm Bowel Dis. 2013;19:1921–7.
  19. Azzopardi N, Ellul P. Disease location and severity may predict vitamin D deficiency in Crohn’s. J Crohns Colitis. 2014;8:1336.
  20. Jørgensen SP, Hvas CL, Agnholt J. Active Crohn’s disease is associated with low vitamin D levels. J Crohns Colitis. 2013;7:e407–13.
  21. Raftery T, Merrick M, Healy M. Vitamin D status is associated with intestinal inflammation as measured by fecal calprotectin in Crohn’s disease in clinical remission. Dig Dis Sci. 2015;60:2427–35.
  22. Vieth R. Vitamin D supplementation, 25-hydroxyvitamin D concentrations, and safety. Am J Clin Nutr 1999;69(5):842–56.
  23. Nesby-O'Dell S, Scanlon KS, Cogswell ME, Gillespie C, Hollis BW, Looker AC, et al. Hypovitaminosis D prevalence and determinants among African American and white women of reproductive age: third National Health and Nutrition Examination Survey, 1988–1994. Am J Clin Nutr 2002;76(1):187–92.
  24. Hollis BW. Circulating 25-hydroxyvitamin D levels indicative of vitamin D sufficiency: implications for establishing a new effective dietary intake recommendation for vitamin D. J Nutr 2005;135(2):317–22.
  25. Hyppönen E, Power C. Hypovitaminosis D in British adults at age 45 y: nationwide cohort study of dietary and lifestyle predictors. Am J Clin Nutr 2007;85(3):860–8.
  26. Wang TJ, Pencina MJ, Booth SL, Jacques PF, Ingelsson E, Lanier K, et al. Vitamin D deficiency and risk of cardiovascular disease. Circulation 2008;117(4):503–11. http://dx.doi.org/10. 1161/CIRCULATIONAHA.107.706127.
  27. Salehpour A, Shidfar F, Hosseinpanah F, Vafa M, Razaghi M, Hoshiarrad A, et al. Vitamin D 3 and the risk of CVD in overweight and obese women: a randomized controlled trial. Br J Nutr 2012;108(10):1866–73. http://dx.doi.org/10.1017/ S0007114512000098.
  28. Hewison M. Vitamin D and the immune system: new perspectives on an old theme. Endocrinol Metab Clin North Am 2010;39(2):365–79.
  29. Cantorna MT. Vitamin D and its role in immunology: multiple sclerosis, and inflammatory bowel disease. Prog Biophys Mol Biol 2006;92(1):60–4. http://dx.doi.org/10.1016/j. pbiomolbio.2006.02.020.
  30. Michos ED, Melamed ML. Vitamin D and cardiovascular disease risk. Curr Opin Clin Nutr Metab Care 2008;11(1):7–12. http://dx.doi.org/10.1097/MCO.0b013e3282f2f4dd.
  31. Vaidya A. Vitamin D and cardio-metabolic disease. Metabolism 2013;62(12):1697.
  32. Wolden-Kirk H, Overbergh L, Christesen HT, Brusgaard K, Mathieu C. Vitamin D and diabetes: its importance for beta cell and immune function. Mol Cell Endocrinol 2011;347(1): 106–20. http://dx.doi.org/10.1016/j.mce.2011.08.016.
  33. Kim HJ, Kang CK, Park H, Lee MG. Effects of vitamin D supplementation and circuit training on indices of obesity and insulin resistance in T2D and vitamin D deficient elderly women. J Exerc Nutr Biochem 2014;18(3):249. http://dx.doi. org/10.5717/jenb.2014.18.3.249.
  34. Chiu KC, Chu A, Go VLW, Saad MF. Hypovitaminosis D is associated with insulin resistance and β cell dysfunction. Am J Clin Nutr 2004;79(5):820–5.
  35. Schuch NJ, Garcia VC, Martini LA. Vitamin D and endocrine diseases. Arq Bras Endocrinol Metab 2009;53(5):625–33.
  36. Norman PE, Powell JT. Vitamin D and cardiovascular disease. Circ Res 2014;114(2):379–93. http://dx.doi.org/10.1161/ CIRCRESAHA.113.301241.
  37. Herrmann M, Sullivan DR, Veillard A, McCorquodale T, Straub IR, Scott R, et al. Serum 25-Hydroxy vitamin D: a predictor of macrovascular and microvascular complications in patients with type 2 diabetes. Diabetes Care 2014;38(3):521–8.
  38. Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J Clin Invest 2005;115(5):1111–9.
  39. Cani PD, Delzenne NM. Gut microflora as a target for energy and metabolic homeostasis. Curr Opin Clin Nutr Metab Care 2007;10(6):729–34. http://dx.doi.org/10.1097/MCO. 0b013e3282efdebb.
  40. Caricilli AM, Picardi PK, de Abreu LL, Ueno M, Prada PO, Ropelle ER, et al. Gut microbiota is a key modulator of insulin resistance in TLR 2 knockout mice. PLoS Biol 2011; 9(12):e1001212.
  41. Moraes ACF, Silva IT, Almeida-Pititto B, Ferreira SRG. Microbiota intestinal e risco cardiometabólico: mecanismos e modulação dietética. Arq Bras Endocrinol Metab 2014;58(4): 317–27. http://dx.doi.org/10.1590/0004-2730000002940.
  42. Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 1998;98(8):731–3. http://dx.doi.org/10.1161/01.CIR. 98.8.731.
  43. Calder PC, Ahluwalia N, Albers R, Bosco N, Bourdet-Sicard R, Haller D, et al. A consideration of biomarkers to be used for evaluation of inflammation in human nutritional studies. Br J Nutr 2013;109(S1):S1–S34. http://dx.doi.org/10.1017/ S0007114512005119.
  44. Almeida-Pititto B, Ribeiro-Filho FF, Bittencourt MS, Lotufo PA, Bensenor I, Ferreira SR. Usefulness of circulating E-selectin to early detection of the atherosclerotic process in the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil). Diabetol Metab Syndr 2016;8(19). http://dx.doi.org/10.1186/s13098-016- 0133-9.
  45. Everard A, Belzer C, Geurts L, Ouwerkerk JP, Druart C, Bindels LB. Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. PNAS 2013;110(22): 9066–71. http://dx.doi.org/10.1073/pnas.1219451110.
  46. Kong J, Zhang Z, Musch MW, Ning G, Sun J, Hart J, et al. Novel role of the vitamin D receptor in maintaining the integrity of the intestinal mucosal barrier. Am J Physiol Gastrointest Liver Physiol 2008;294:G208–16. http://dx.doi.org/10.1152/ ajpgi.00398.2007.
  47. Ooi JH, Li Y, Rogers CJ, Cantorna MT. Vitamin D regulates the gut microbiome and protects mice from dextran sodium sulfate-induced colitis. J Nutr 2013;143(10):1679–86.
  48. Bashir M, Prietl B, Tauschmann M, Mautner SI, Kump PK, Treiber G, et al. Effects of high doses of vitamin D3 on mucosa-associated gut microbiome vary between regions of the human gastrointestinal tract. Eur J Nutr 2015;55:1479–89. http://dx.doi.org/10.1007/s00394-015-0966-2.
  49. Mai V, McCrary QM, Sinha R, Glei M. Associations between dietary habits and body mass index with gut microbiota composition and fecal water genotoxicity: an observational study in African American and Caucasian American volunteers. Nutr J 2009;8(1):49. http://dx.doi.org/10.1186/1475-2891- 8-49.
  50. Ly NP, Litonjua A, Gold DR, Celedón JC. Gut microbiota, probiotics, and vitamin D: interrelated exposures influencing allergy, asthma, and obesity? J Allergy Clin Immunol 2011; 127(5):1087–94. http://dx.doi.org/10.1016/j.jaci.2011.02.015.
  51. Ciubotaru I, Green SJ, Kukreja S, Barengolts E. Significant differences in fecal microbiota are associated with various stages of glucose tolerance in African American male veterans. Transl Res 2015;166(5):401–11. http://dx.doi.org/10. 1016/j.trsl.2015.06.015.
  52. Folchetti LGD, da Silva IT, de Almeida-Pititto B, Ferreira SRG Nutritionists' Health Study cohort: a web-based approach of life events, habits and health outcomes. BMJ Open 2016; 6(8):e012081. http://dx.doi.org/10.1136/bmjopen-2016-012081.
  53. Guyton AC, Hall JE. Textbook of medical physiology. 11th ed. Philadelphia: Saunders; 2006.
  54. Matsudo S, Araújo T, Marsudo V, Andrade D, Andrade E, Braggion G. Questinário internacional de atividade física (IPAQ): estudo de validade e reprodutibilidade no Brasil. Ver.Bras Ativ Fís Saúde 2001;6(2):05–18.
  55. Craig CL, Marshall AL, Sjöström M, Bauman AE, Booth ML, Ainsworth BE, et al. International physical activity questionnaire: 12-country reliability and validity. Med Sci Sports Exerc 2003;35(8):1381–95. http://dx.doi.org/10.1249/01.MSS. 0000078924.61453.FB.
  56. Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, et al. Endocrine Society. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011;96(7):1911– 30. http://dx.doi.org/10. 1210/jc.2011-0385.
  57. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28:412–9. http://dx.doi.org/10.1007/BF00280883.
  58. Caporaso JG, Lauber CL, Walters W, Berg-Lyons D, Huntley J, Fierer N, et al. Ultra-highthroughput microbial community analysis on the Illumina HiSeq and MiSeq platforms. ISME J 2012;6(8):1621–4. http://dx.doi.org/10.1038/ismej.2012.8.
  59. Forman JP, Giovannucci E, Holmes MD, Bischoff-Ferrari HA, Tworoger SS,Willett WC, et al. Plasma 25-hydroxyvitamin D levels and risk of incident hypertension. Hypertension 2007; 49(5):1063–9. http://dx.doi.org/10.1161/HYPERTENSIONAHA.107.087288.
  60. Shankar A, Sabanayagam C, Kalidindi S. Serum 25- hydroxyvitamin D levels and prediabetes among subjects free of diabetes. Diabetes Care 2011;34(5):1114–9. http://dx. doi.org/10.2337/dc10-1203.
  61. Salehpour A, Hosseinpanah F, Shidfar F, Vafa M, Razaghi M, Dehghani S, et al. A 12week double-blind randomized clinical trial of vitamin D3 supplementation on body fat mass in healthy overweight and obese women. Nutr J 2012;11(1):78. http://dx.doi.org/10.1201/b16308-3.
  62. Ryz NR, Lochner A, Bhullar K, Ma C, Huang T, Bhinder G, et al. Dietary vitamin D3 deficiency alters intestinal mucosal defense and increases susceptibility to Citrobacter rodentium induced colitis 2. Am J Physiol Gastrointest Liver Physiol 2015;309(9):G730– 42.
  63. Jorde R, Sollid ST, Svartberg J, Schirmer H, Joakimsen RM, Njølstad I, et al. Vitamin D 20 000 IU per week for five years does not prevent progression from prediabetes to diabetes. J Clin Endocrinol Metab 2016;101(4):1647–55. http://dx.doi.org/10.1210/jc.2015-4013.
  64. Mora JR, Iwata M, von Andrian UH. Vitamin effects on the immune system: vitamins A and D take centre stage. Nat Rev. Immunol 2008;8(9):685–98. http://dx.doi.org/10.1038/nri2378.
  65. Hewison M. An update on vitamin D and human immunity. Clin Endocrinol (Oxf) 2012;76:315–25. http://dx.doi.org/10. 1111/j.1365-2265.2011.04261.x.
  66. Bellia A, Garcovich C, D'Adamo M, Lombardo M, Tesauro M, Donadel G, et al. Serum 25-hydroxyvitamin D levels are inversely associated with systemic inflammation in severe obese subjects. Intern Emerg Med 2013;8(1):33–40. http://dx. doi.org/10.1007/s11739011-0559-x.
  67. Mellenthin L, Wallaschofski H, Grotevendt A, Völzke H, Nauck M, Hannemann A. Association between serum vitamin D concentrations and inflammatory markers in the general adult population. Metab Clin Exp 2014;63(8):1056–62.
  68. Cantorna MT, McDaniel K, Bora S, Chen J, James J. Vitamin D, immune regulation, the microbiota, and inflammatory bowel disease. Exp Biol Med 2014;239(11):1524–30. http://dx.doi.org/ 10.1177/1535370214523890.
  69. Arumugam M, Raes J, Pelletier E, Le Paslier D, Yamada T, Mende DR, et al. Enterotypes of the human gut microbiome. Nature 2011;473:174–80.
  70. Qin J, Li Y, Cai Z, Li S, Zhu J, Zhang F, et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature 2012;490(7418):55–60. http://dx.doi.org/10.1038/nature11450.
  71. Wu GD, Chen J, Hoffmann C, Bittinger K, Chen YY, Keilbaugh SA, et al. Linking longterm dietary patterns with gut microbial enterotypes. Science 2011;334(6052):105–8. http:// dx.doi.org/10.1126/science.1208344.
  72. Said HS, SudaW,Nakagome S, ChinenH, Oshima K, KimS, et al. Dysbiosis of salivarymicrobiota in inflammatory bowel disease and its association with oral immunological biomarkers. DNA Res 2013;037. http://dx.doi.org/10.1093/dnares/dst037.
  73. Van den Bogert B, Meijerink M, Zoetendal EG, Wells JM, Kleerebezem M. Immunomodulatory properties of Streptococcus and Veillonella isolates from the human small intestine microbiota. PLoS One 2014;9(12):e114277. http://dx.doi.org/10. 1371/journal.pone.0114277.
  74. Sokol H, Pigneur B, Watterlot L, Lakhdari O, Bermúdez- Humarán LG, Gratadoux JJ, et al. Faecalibacterium prausnitziiisan anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci U S A 2008;105:16731–6.
  75. Collado MC, Isolauri E, Laitinen K, Salminen S. Distinct composition of gut microbiota during pregnancy in overweight and normal-weight women. Am J Clin Nutr 2008;88(4): 894–9.
  76. Wu X, Ma C, Han L, Nawaz M, Gao F, Zhang X, et al. Molecular characterisation of the faecal microbiota in patients with type II diabetes. Curr Microbiol 2010;61:69–78. http://dx.doi. org/10.1007/s00284-010-9582-9.
  77. Cantarel BL, Waubant E, Chehoud C, Kuczynski J, DeSantis TZ, Warrington J, et al. Gut microbiota in multiple sclerosis. J Invest Med 2015;63(5):729–34. http://dx.doi.org/10.1097/JIM. 0000000000000192.
  78. Zhang Y, Leung DY, Richers BN, Liu Y, Remigio LK, Riches DW, et al. Vitamin D inhibits monocyte/macrophage proinflammatory cytokine production by targeting MAPK phosphatase-1. J Immunol 2012;188(5):2127–35. http://dx.doi. org/10.4049/jimmunol.1102412.
  79. Cantorna MT. Mechanisms underlying the effect of vitamin D on the immune system. Proc Nutr Soc 2010;69(03):286–9. http://dx.doi.org/10.1017/S0029665110001722.
  80. Mangin M, Sinha R, Fincher K. Inflammation and vitamin D: the infection connection. Inflamm Res 2014;63(10):803–19. http://dx.doi.org/10.1007/s00011-014-0755-z.
  81. Assa A, Vong L, Pinnell LJ, Avitzur N, Johnson-Henry KC, Sherman PM. Vitamin D deficiency promotes epithelial barrier dysfunction and intestinal inflammation. J Infect Dis. 2014;210:1296–305. http://dx.doi.org/10.1093/infdis/jiu235.
  82. Jones BJ, Twomey PJ. Issues with vitamin D in routine clinical practice. Rheumatology 2008; 47:1267-68.
  83. Cantorna MT. Vitamin D and autoimmunity: is vitamin D status an environmental factor affecting autoimmune disease prevalence? Proc Soc Exp Biol Med 2000; 223:230-3.
  84. Kamen DL, Cooper GS, Bouali H, Shaftman SR, Hollis BW, Gilkeson GS. Vitamin D deficiency in systemic lupus erythematosus. Autoimmun Rev 2006; 5:114-7.
  85. Lipps, P. Which circulating level of 25-hydroxyvitamin D is appropriate? J Steroid Biochem Mol Biol 2004: 611-4.
  86. Cantorna MT, Mahon B. Mounting evidence for vitamin D as an environmental factor affecting autoimmune disease prevalence. Exp Bio Med (Maywood) 2004; 229(11):113642.
  87. Lemire JM, Ince A, Takashima M. 1,25-Dihydroxyvitamin D3 attenuates the expression of experimental murine lupus of MRL/I mice. Autoimmunity 1992; 12(2):143-8.
  88. Linker-Israeli M, Elstner E, Klinenberg JR, Wallace DJ, Koeffler HP. Vitamin D(3) and its synthetic analogs inhibit the spontaneous in vitro immunoglobulin production by SLEderived PBMC. Clin.Immunol 2001; 99:82-93.
  89. Arnson Y, Amital H, Shoenfeld Y. Vitamin D and autoimmunity: new etiological and therapeutic considerations. Ann Rheum Dis 2007; 66:1137-42.
  90. Bringhurst FR, Demay MB, Kronenberg HM. Hormones and Disorders of Mineral Metabolism. In: Kronenberg HM, Melmed S, Polonsky KS, Larsen PR editors. Williams Textbook of Endocrinology, 11 ed. Philadelphia: Elsevier, 2008.
  91. Leventis P, Patel S. Clinical aspects of vitamin D in the management of rheumatoid arthritis. Rheumatology 2008; 47:1617-21.
  92. Szodoray P, Nakken B, Gaal J, Jonsson R, Szegedi A, Zold E et al. The complex role of vitamin D in autoimmune diseases. Scand J Immunol 2008; 68(3):261-9.
  93. Deluca HF, Cantorna MT. Vitamin D – its role and uses in immunology. FASEB Journal 2001; 15:2579-85.
  94. Ruiz-Irastorza G, Egurbide MV, Olivares N, Martinez-Berriotxoa A, Aguirre C. Vitamin D deficiency in systemic lupus erythematosus: prevalence, predictors and clinical consequences. Rheumatology 2008; 47:920-3.
  95. Nagpal S, Na S, Rathnachalam R. Noncalcemic actions of vitamin D receptor ligands. Endocrine Reviews 2005; 26(5):662-87.
  96. Bandeira F, Griz L, Dreyer P, Eufrazino C, Bandeira C, Freese E. Vitamin D deficiency: a global perspective. Arq Bras Endocrinol Metabol 2006; 50(4):640-6.
  97. Lamb EJ, Wong T, Smith DJ, Simpson DE, Coakley AJ, Moniz C. Metabolic bone disease is present at diagnosis in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2002; 16(11):1985-92.
  98. Cutolo M. Vitamin D and autoimmune rheumatic diseases. Rheumatology 2009; 48: 210-2.
  99. Holick MF. Vitamin D: importance in the prevention of cancers, type 1 diabetes, heart disease and osteoporosis. Am J Clin Nutr 2004; 79:362-71.
  100. Cutolo M, Otsa K. Review: vitamin D, immunity and lupus. Lupus 2008; 17:6-10.
  101. Steinman L. A brief history of TH17, the first major revision in the TH1/TH2 hypothesis of T cell-mediated tissue damage. Nat Med 2007; 13:139-45.
  102. Yu S, Cantorna MT. The vitamin D receptor is required for iNKT cell development. Proc Natl Acad Sci USA 2008; 105:5207-12.
  103. Adorini A, Penna G. Control of autoimmune diseases by the vitamin D endocrine system. Nat Clin Pract Rheumatol 2008; 4:404-12.
  104. Harris Jr ED, Schur PH. Pathogenesis of rheumatoid arthritis. In: UpToDate, Basow, DS (Ed), UpToDate, Waltham, MA, 2007.
  105. Manolagas SC, Werntz DA, Tsoukas CD, Provvedini DM, Vaughan JH. 1,25-dihydroxyvitamin D3 receptors in lymphocytes from patients with rheumatoid arthritis. J Lab Clin Med 1986; 108:596-600.
  106. Gomez-Vaquero C, Fiter J, Enjuanes A, Nogues X, Diez-Perez A, Nolla JM. Influence of the Bsml polymorphism of the vitamin D receptor gene on rheumatoid arthritis clinical activity. J Rheumatol 2007; 34:1823-6.
  107. Tsuji M, Fujii K, Nakano T, Nishii Y. 1994 1a-hydroxyvitamin D3 inhibits type II collagen-induced arthritis in rats. FEBS Lett 1994; 337:248-50.
  108. Merlino LA, Curtis J, Mikuls TR, Cerhan JR, Criswell LA, Saag KG. Vitamin D intake is inversely associated with rheumatoid arthritis. Arthritis Rheum 2004; 50(1):72-7.
  109. Costenbader KH, Feskanich D, Holmes M, Karlson EW, Benito- Garcia E. Vitamin D intake and risks of systemic lupus erythematosus and rheumatoid arthritis in women. Ann Rheum Dis 2008; 67:530-5.
  110. Nielen MMJ, Schaardenburg D, Lems WF, van de Stadt RJ, de Koning MHM, Reesink HW et al. Vitamin D deficiency does not increase the risk of rheumatoid arthritis: comment on the article by Merlino et al. Arthritis Rheum 2006; 54(11): 3719-24.
  111. Andjelkovic Z, Vojinovic J, Pejnovic N, Popovic M, Dujic A, Mitrovic D. Disease modifying and immunomodulatory effects of high dose 1a(OH) D3 in rheumatoid arthritis patients. Clin Exper Rheumatol 1999; 17:453-6.
  112. Huisman AM, White KP, Algra A, Harth M, Vieth R, Jacobs JW. Vitamin D levels in women with systemic lupus erythematosus and fibromyalgia. J Rheumatol 2001; 28:2535-39.
  113. Thudi A, Yin S, Wandstrat AE, Li QZ, Olsen NJ. Vitamin D levels and disease status in Texas patients with systemic lupus erythematosus. Am J Med Sci 2008; 335:99104.
  114. Borba VZC, Vieira JGH, Kasamatsu T, Radominski SC, Sato EI, Lazaretti-Castro M. Vitamin D deficiency in patients with active systemic lupus erythematosus. Osteoporos Int 2009; 20:427-33.
  115. Carvalho JF, Blank M, Kiss E, Tarr T, Amital H, Shoenfeld Y. Antivitamin D in SLE: preliminary results. Ann N Y Acad Sci 2007; 1109:550-7.
  116. Zold E, Szodoray P, Gaal J, Kappelmayer J, Csathy L, Gyimesi E. Vitamin D deficiency in undifferentiated connective tissue disease. Arthritis Res Ther 2008; 10: R123.
  117. Jahnsen J, Falch JA, Mowinckel P, Aadland E. Vitamin D status, parathyroid hormone and bone mineral density in patients with inflammatory bowel disease. Scand J Gastroenterol 2002; 37:192-9.

How to Cite

Nabuth, M. P. (2023). Major clinical outcomes of vitamin D deficiency in inflammatory bowel diseases: a systematic and integrative review. International Journal of Nutrology, 16(2). https://doi.org/10.54448/ijn23225